National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2012 (No. 1) (No. PB 8 of 2012) (Cth)
PB 8 of 2012
National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2012 (No.1)
National Health Act 1953
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.
Dated 27 February 2012
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
1 Name of Instrument
(1) This Instrument is the National Health (Growth Hormone Program)
Special Arrangement Amendment Instrument 2012 (No.1).
(2) This Instrument may also be cited as PB 8 of 2012.
2 Commencement
(1) Sections 1 to 3 and Schedule 1 are taken to have commenced on
1 December 2011.
(2) Schedule 2 commences on 1 March 2012.
3 Amendment of PB 88 of 2011
Schedules 1 and 2 amend the National Health (Growth Hormone Program) Special Arrangement 2011 (PB 88 of 2011).
Schedule 1 Amendments
Subsection 47(2),
substitute:
(2) However, if the form of the pharmaceutical benefit and the manufacturer’s pack is unable to accommodate the dose level mentioned
in the item of the table that applies to a person, the dose of pharmaceutical benefit that the Secretary determines:
(a) for a person eligible for the maximum dose level of an item of the table – may be within 3% of the maximum dose level of the item of the table that applies to the person; or
(b) for any other person – may be the closest available dose to a dose level mentioned in the table that applies to the person.
(2A) If paragraph (2)(a) or (b) applies, the dose determined by the Secretary is taken to be the dose level mentioned in the item.
Schedule 2 Amendments
[1] Schedule 1, after
| Injection 18 i.u. (6 mg) cartridge with 3.15 mL diluent (with preservative) | Injection | Humatrope | LY | AMP | D |
insert:
| Solution for injection 6 mg (18 i.u.) in 1.03 mL cartridge (with preservative) | Injection | Saizen | SG | AMP | D |
Schedule 1, after
| Powder for injection 12 mg (36 i.u.) with diluent in pre-filled pen (with preservative) | Injection | Genotropin GoQuick | PF | AMP | D |
insert:
| Solution for injection 12 mg (36 i.u.) in 1.5 mL cartridge (with preservative) | Injection | Saizen | SG | AMP | D |
Schedule 1, after
| Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative) | Injection | Norditropin NordiFlex | NO | AMP | D |
| Norditropin FlexPro | NO | AMP | D | ||
| Norditropin SimpleXx | NO | AMP | D |
insert:
| Solution for injection 20 mg (60 i.u.) in 2.5 mL cartridge (with preservative) | Injection | Saizen | SG | AMP | D |
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the
Legislative Instruments Act 2003. See
0
0
0